New radioactive drug targets thyroid tumors in early trial
NCT ID NCT07438847
First seen Feb 27, 2026 · Last updated May 16, 2026 · Updated 8 times
Summary
This early-phase study is testing a new radioactive drug called 177Lu-CTR-FAPI in 12 people with thyroid cancer that has spread and is no longer responding to standard treatments. The main goals are to find a safe dose and see if the drug can shrink tumors or slow the disease. This is a first step to see if the approach is worth studying further.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for THYROID CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College
RECRUITINGBeijing, 100021, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Peking Union Medical College Hospital
RECRUITINGBeijing, 100730, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.